Search results
Showing 661 to 675 of 739 results for impact reports
improving identification and referral rates consists mainly of observational reports of complex interventions, with most studies being...
Day-to-day decision making is the responsibility of NICE's executive team.
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
How we collect and use your personal information, and your rights under data protection legislation.
Outside interests of the NICE board
Learning disability: care and support of people growing older (QS187)
This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.
View quality statements for QS187Show all sections
Recommendation ID NG61/2 Question Perinatal palliative care:- What impact does timely perinatal palliative care have on the experience...
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Evidence-based recommendations on transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula. This involves inserting a catheter through the femoral vein and injecting embolisation liquid to seal the fistula.
Show all sections
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults.